The amyloid beta theory that has driven billions of dollars in failed Alzheimer’s research has taken yet another body blow. Roche — and specifically its big sub Genentech — conceded defeat overnight for its closely watched crenezumab in the Phase II API-ADAD trial in Alzheimer’s prevention. This follows twin Phase…
...